According to the FDA, the agency has issued a tentative approval of an application by PulmoFlow, Inc. to market tobramycin 300 mg/5 ml inhalation solution.
PulmoFlow, Inc. was established in Virginia in 2013. The company’s web site is a single page that says “PulmoFlow is a newly established company currently focused on solutions to improve the lives of patients with acute and chronic respiratory indications.” Also, according to the site, the company is “a dedicated licensing entity with a focus on pediatric, respiratory, and orphan indications” and is open to “possibilities of collaboration.”
A number of trademark applications for the name “PulmoFlow” have been submitted by PARI over the years, and PulmoFlow GmbH is listed at the same address as PARI GmbH.
